The New England journal of medicine, 2020-12, Vol.383 (24), p.2345-2357
- Hussain, Maha
- Mateo, Joaquin
- Fizazi, Karim
- Saad, Fred
- Shore, Neal
- Sandhu, Shahneen
- Chi, Kim N
- Sartor, Oliver
- Agarwal, Neeraj
- Olmos, David
- Thiery-Vuillemin, Antoine
- Twardowski, Przemyslaw
- Roubaud, Guilhem
- Özgüroğlu, Mustafa
- Kang, Jinyu
- Burgents, Joseph
- Gresty, Christopher
- Corcoran, Claire
- Adelman, Carrie A
- de Bono, Johann
2020
Details
- Autor(en) / Beteiligte
- Hussain, Maha
- Mateo, Joaquin
- Fizazi, Karim
- Saad, Fred
- Shore, Neal
- Sandhu, Shahneen
- Chi, Kim N
- Sartor, Oliver
- Agarwal, Neeraj
- Olmos, David
- Thiery-Vuillemin, Antoine
- Twardowski, Przemyslaw
- Roubaud, Guilhem
- Özgüroğlu, Mustafa
- Kang, Jinyu
- Burgents, Joseph
- Gresty, Christopher
- Corcoran, Claire
- Adelman, Carrie A
- de Bono, Johann
- Titel
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- Ist Teil von
- The New England journal of medicine, 2020-12, Vol.383 (24), p.2345-2357
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The PROfound trial showed that olaparib prolonged imaging-based progression-free survival among patients whose tumors contained defects in the homologous recombination repair genes BRCA1 , BRCA2 , or ATM . With longer follow-up, the trial now shows that olaparib prolonged overall survival in these patients. Toxic effects included anemia, nausea, and asthenia.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2022485Titel-ID: cdi_proquest_journals_2468693154
- Format
- –
- Schlagworte
- Aged, Aged, 80 and over, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Ataxia Telangiectasia Mutated Proteins - genetics, BRCA1 protein, BRCA2 protein, Bridged-Ring Compounds - therapeutic use, Cancer therapies, Castration, Confidence intervals, Cyclin-Dependent Kinases - genetics, Drug therapy, Genes, BRCA1, Homologous recombination, Homologous recombination repair, Humans, Male, Medical prognosis, Metastases, Metastasis, Middle Aged, Mutation, Neoplasm Metastasis - drug therapy, Patient outcomes, Patients, Phthalazines - adverse effects, Phthalazines - therapeutic use, Piperazines - adverse effects, Piperazines - therapeutic use, Prednisone, Prostate cancer, Prostatic Neoplasms, Castration-Resistant - drug therapy, Prostatic Neoplasms, Castration-Resistant - genetics, Prostatic Neoplasms, Castration-Resistant - mortality, Prostatic Neoplasms, Castration-Resistant - pathology, Sensitivity analysis, Statistical analysis, Survival, Survival Analysis, Taxoids - therapeutic use, Tumors